About the Event
Over the past few years, mRNA medicines have been front-and-center in public discourse due to the COVID-19 pandemic, and the development of the COVID-19 vaccine is a case study in the ability of science and technology to aid humanity in moments of need. With the success of the mRNA COVID-19 vaccines, this previously little-known technology is spearheading the next wave of precision genetic medicines. Starting with the central dogma of molecular biology, Moderna’s story of the commercializing mRNA-1273 (the COVID-19 vaccine) will be explored, as well as the future of this exciting new frontier of biotechnology.
About the Speaker
Jason Murphy Ph.D., Vice President and Head of DNA and Chemical Operations and Strategy
Jason Murphy, Ph.D., joined Moderna in 2018 and currently leads the DNA and Chemistry Business Unit with prior roles within Moderna’s Technical Development Organization. Prior to joining Moderna, Murphy was at Eli Lilly and Company for 3 years leading fermentation and strain development as well as Biopharmaceutical Technical Services and spent 14 years at Merck & Co. in various roles within Merck Research Labs and the Merck Manufacturing Division. Murphy is a Chemical Engineer by training with Ph.D. and M.S. degrees from the University of Houston (Advised by Professor Richard Willson) and a B.S. degree from University of California at Berkeley.
Please direct any questions to: Nadine Peterson, DDI Coordinator at ddicoordinator@gmail.com
